| S. No. |
Biomarker |
Endometrium cell line |
Prostate cell line |
| Control |
Treated |
% change |
Control |
Treated |
% change |
| 1 |
IL-2R (U/ml) |
<50.0 |
<50.0 |
NC |
<50.0 |
<50.0 |
NC |
| 2 |
IL-6 (pg/ml) |
4.0 |
3.52 |
-12 |
165 |
< 2.0 |
-98.8 |
| 3 |
TNF-α (pg/ml) |
4.23 |
20.5 |
385 |
< 4.0 |
7.59 |
89.8 |
| 4 |
PSA (ng/ml) |
< 0.003 |
< 0.003 |
NC |
< 0.003 |
0.003 |
NC |
| 5 |
FPSA (ng/ml) |
< 0.05 |
< 0.05 |
NC |
< 0.05 |
< 0.05 |
NC |
|
| NC: No change; pg/ml: picogram per milliliter; ng/ml: Nano gram per milliliter; U/ml: Unit per milliliter; IL-2R: Interleukin-2 receptor; IL-6: Interleukin-6; TNF-α: Tumor necrosis
factor alpha; PSA: Prostate specific antigen; FPSA: Free prostate specific antigen. |
| Table 1: Effect of biofield treatment on cancer biomarker concentration in endometrium and prostate cancer cell lines. |
